ADVOCATE. CONNECT. INNOVATE.

CLSA Wire

CLSA featured on KSRO AM/FM Sharing Life Sciences Sector Concerns With SB 17
Facebook
Twitter
LinkedIn

August 22, 2017

As the Legislature returns from their summer break, numerous bills of importance to the life sciences sector, including Senate Bill 17, are poised to be considered by the Assembly in the coming weeks. SB 17 would require an advance notice of price increases on many drugs to all California payers and the submission of a litany of information to the state on those drugs.

Today, CLSA’s Brett Johnson, Senior Director of Policy and Regulatory Affairs, was featured on Sonoma County’s News Talk KSRO 103.5 FM/1350 AM commenting on the shortcomings of the measure, and sharing life sciences sector concerns with SB 17. Listen below.

About SB 17

SB 17 would require, among many other things, industry to provide a 60-day advance notice of any price increase on a drug to all California public agency purchasers, health insurers, and pharmacy benefit managers (PBM) if that drug’s price increased 10 percent or more cumulatively over the previous two calendar years. On the date of the increase, the drug’s manufacturer would have to submit a host of information to the state, including proprietary information like expected marketing budgets for the drug. This information would then be posted publicly by the state in a manner that allows identification of the individual drugs. SB 17 is currently before the Assembly Appropriations Committee. CLSA and our partner trade associations are advocating for amendments to make the bill less administratively burdensome and costly for the industry, as well as requesting the same confidentiality protections granted to insurers under the bill. Learn more about SB 17.